Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-048689
Filing Date
2025-05-14
Accepted
2025-05-14 20:39:59
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6073
  Complete submission text file 0001104659-25-048689.txt   8052
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Subject) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-42217 | Film No.: 25948095
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O 115 CHURCH STREET CHARLESTON SC 29401
Business Address C/O 115 CHURCH STREET CHARLESTON SC 29401 843-270-4171
IAF, LLC (Filed by) CIK: 0001989492 (see all company filings)

EIN.: 873482819 | State of Incorp.: SC | Fiscal Year End: 1231
Type: SCHEDULE 13G/A